A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Conditions: Cancer; Heart Failure; Arrhythmia; Doxorubicin Induced Cardiomyopathy; Doxorubicin Adverse Reaction Interventions: Drug: Control group:DH001 placebo; Drug: Trial group: DH001 low-dose group; Drug: Trial group: DH001 high-dose group Sponsors: Monyan Pharmaceutical (Shanghai) Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arrhythmia | Cancer | Cancer & Oncology | Cardiology | Cardiomyopathy | Clinical Trials | Heart | Heart Failure | Research